Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.04
AIQ's Cash-to-Debt is ranked lower than
96% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. AIQ: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
AIQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: N/A
Current: 0.04
Equity-to-Asset -0.22
AIQ's Equity-to-Asset is ranked lower than
94% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AIQ: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
AIQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39  Med: -0.09 Max: 0.04
Current: -0.22
-0.39
0.04
Interest Coverage 1.43
AIQ's Interest Coverage is ranked lower than
93% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. AIQ: 1.43 )
Ranked among companies with meaningful Interest Coverage only.
AIQ' s Interest Coverage Range Over the Past 10 Years
Min: 0.27  Med: 1.38 Max: 2.08
Current: 1.43
0.27
2.08
Piotroski F-Score: 5
Altman Z-Score: 0.78
Beneish M-Score: -3.19
WACC vs ROIC
4.87%
9.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 9.97
AIQ's Operating Margin % is ranked higher than
65% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. AIQ: 9.97 )
Ranked among companies with meaningful Operating Margin % only.
AIQ' s Operating Margin % Range Over the Past 10 Years
Min: -29.79  Med: 9.43 Max: 14.34
Current: 9.97
-29.79
14.34
Net Margin % 0.21
AIQ's Net Margin % is ranked higher than
51% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. AIQ: 0.21 )
Ranked among companies with meaningful Net Margin % only.
AIQ' s Net Margin % Range Over the Past 10 Years
Min: -32.43  Med: 0.1 Max: 3.65
Current: 0.21
-32.43
3.65
ROA % 0.17
AIQ's ROA % is ranked higher than
55% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. AIQ: 0.17 )
Ranked among companies with meaningful ROA % only.
AIQ' s ROA % Range Over the Past 10 Years
Min: -21.65  Med: 0.07 Max: 2.18
Current: 0.17
-21.65
2.18
ROC (Joel Greenblatt) % 24.86
AIQ's ROC (Joel Greenblatt) % is ranked higher than
69% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. AIQ: 24.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AIQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -47.29  Med: 16.89 Max: 28.87
Current: 24.86
-47.29
28.87
3-Year Revenue Growth Rate 3.00
AIQ's 3-Year Revenue Growth Rate is ranked lower than
60% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. AIQ: 3.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AIQ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.7  Med: 1.3 Max: 27
Current: 3
-4.7
27
3-Year EBITDA Growth Rate 7.60
AIQ's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. AIQ: 7.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AIQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: -3.1 Max: 151.8
Current: 7.6
-20.5
151.8
GuruFocus has detected 4 Warning Signs with Alliance HealthCare Services Inc $AIQ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AIQ's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 622310    SIC: 8069
Compare:NAS:TRIB, NAS:PMD, NAS:FLGT, OTCPK:CBIS, NAS:CTSO, NAS:TTOO, NAS:FLDM, AMEX:SENS, NAS:VRML, OTCPK:CLIFF, OTCPK:EPGNF, NAS:MGEN, AMEX:VNRX, NAS:CEMI, NAS:CGIX, OTCPK:EDTXF, OTCPK:ANPCY, AMEX:PTN, NAS:BIOC, OTCPK:PRFMF » details
Traded in other countries:AI6M.Germany,
Headquarter Location:USA
Alliance HealthCare Services Inc through its subsidiaries provides outsourced healthcare services to hospitals and providers. It also operates freestanding outpatient radiology, oncology and interventional clinics, and Ambulatory Surgical Centers.

Alliance HealthCare Services Inc Its diagnostic imaging services include magnetic resonance imaging technology and positron emission tomography/computed tomography services that generate representations of the internal anatomy and convert them to film or digital media. The Company operates in two reportable segments, Imaging and Radiation Oncology. It offers non scan-based services, which comprise the use of imaging systems under a short-term contract. In addition, it provides radiation oncology services that include conventional beam therapy, 3-D conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, stereotactic radiosurgery, low dose rate brachytherapy, and high dose rate brachytherapy for the treatment of cancer; and stereotactic radiation oncology services. Further, the Company offers ancillary services, such as marketing support, education, training, and billing assistance. It provides imaging and therapeutic services through hospitals and clinics, independent imaging and radiation oncology centers, and other healthcare providers on a shared-service and full-time service basis, as well as provides services through fixed-sites, primarily to hospitals or health systems. It competes with RadNet, Inc., Center for Diagnostic Imaging. The Company is subject to federal and state government regulations. It is also subject to various environmental, health, and safety laws regulated by the government.

Ratios

vs
industry
vs
history
PE Ratio 147.23
AIQ's PE Ratio is ranked lower than
93% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.54 vs. AIQ: 147.23 )
Ranked among companies with meaningful PE Ratio only.
AIQ' s PE Ratio Range Over the Past 10 Years
Min: 7.76  Med: 24.43 Max: 625
Current: 147.23
7.76
625
PE Ratio without NRI 147.23
AIQ's PE Ratio without NRI is ranked lower than
93% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.74 vs. AIQ: 147.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
AIQ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.76  Med: 24.43 Max: 625
Current: 147.23
7.76
625
Price-to-Owner-Earnings 4.39
AIQ's Price-to-Owner-Earnings is ranked higher than
99% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.56 vs. AIQ: 4.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AIQ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.62  Med: 7.12 Max: 22.32
Current: 4.39
1.62
22.32
PS Ratio 0.28
AIQ's PS Ratio is ranked higher than
98% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. AIQ: 0.28 )
Ranked among companies with meaningful PS Ratio only.
AIQ' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.52 Max: 1.29
Current: 0.28
0.08
1.29
Price-to-Free-Cash-Flow 2.67
AIQ's Price-to-Free-Cash-Flow is ranked higher than
99% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. AIQ: 2.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AIQ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.74  Med: 4.68 Max: 28.19
Current: 2.67
0.74
28.19
Price-to-Operating-Cash-Flow 1.37
AIQ's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. AIQ: 1.37 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AIQ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.44  Med: 2.14 Max: 4.75
Current: 1.37
0.44
4.75
EV-to-EBIT 15.59
AIQ's EV-to-EBIT is ranked higher than
77% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AIQ: 15.59 )
Ranked among companies with meaningful EV-to-EBIT only.
AIQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -342.9  Med: 14.9 Max: 77.4
Current: 15.59
-342.9
77.4
EV-to-EBITDA 6.72
AIQ's EV-to-EBITDA is ranked higher than
93% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. AIQ: 6.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
AIQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.1  Med: 6.3 Max: 10.2
Current: 6.72
-18.1
10.2
Current Ratio 1.09
AIQ's Current Ratio is ranked lower than
85% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. AIQ: 1.09 )
Ranked among companies with meaningful Current Ratio only.
AIQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 2.87
Current: 1.09
1
2.87
Quick Ratio 1.09
AIQ's Quick Ratio is ranked lower than
80% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. AIQ: 1.09 )
Ranked among companies with meaningful Quick Ratio only.
AIQ' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 2.87
Current: 1.09
1
2.87
Days Sales Outstanding 53.27
AIQ's Days Sales Outstanding is ranked higher than
60% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. AIQ: 53.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
AIQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.7  Med: 50.62 Max: 56.49
Current: 53.27
44.7
56.49
Days Payable 34.09
AIQ's Days Payable is ranked lower than
73% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. AIQ: 34.09 )
Ranked among companies with meaningful Days Payable only.
AIQ' s Days Payable Range Over the Past 10 Years
Min: 18.28  Med: 28.73 Max: 36
Current: 34.09
18.28
36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
AIQ's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. AIQ: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AIQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.7  Med: -1.2 Max: 7.1
Current: -0.4
-67.7
7.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.49
AIQ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. AIQ: 0.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AIQ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.17  Med: 0.7 Max: 4.31
Current: 0.49
0.17
4.31
Price-to-Median-PS-Value 0.55
AIQ's Price-to-Median-PS-Value is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. AIQ: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AIQ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.13 Max: 4.06
Current: 0.55
0.21
4.06
Earnings Yield (Greenblatt) % 6.41
AIQ's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. AIQ: 6.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AIQ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24.2  Med: 6.2 Max: 11.2
Current: 6.41
-24.2
11.2
Forward Rate of Return (Yacktman) % 32.91
AIQ's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. AIQ: 32.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AIQ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.2  Med: 18.95 Max: 148.5
Current: 32.91
5.2
148.5

More Statistics

Revenue (TTM) (Mil) $511.76
EPS (TTM) $ 0.09
Beta0.35
Short Percentage of Float0.96%
52-Week Range $5.73 - 13.60
Shares Outstanding (Mil)10.83
» More Articles for AIQ

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 

More From Other Websites
Acquisition of Hong Kong Dah Sing Life by Tahoe Investment Group Jun 19 2017
Alliance Healthcare Services, Inc. -- Moody's affirms Alliance Healthcare Services CFR at B1, lowers... Jun 13 2017
ETFs with exposure to Alliance HealthCare Services, Inc. : June 9, 2017 Jun 09 2017
Alliance HealthCare Services, Inc. :AIQ-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6,... Jun 06 2017
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Alliance Healthcare... May 23 2017
Edited Transcript of AIQ earnings conference call or presentation 9-May-17 9:00pm GMT May 17 2017
Alliance Oncology Partners with Red Rocks Radiation and Oncology, LLC May 09 2017
Alliance HealthCare reports 1Q loss May 09 2017
Alliance Healthcare Services Reports Results for the First Quarter Ended March 31, 2017 May 09 2017
Investor Network: Alliance HealthCare Services, Inc. to Host Earnings Call May 09 2017
Alliance HealthCare Services, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe... May 02 2017
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Alliance HealthCare Services,... May 01 2017
Lifshitz & Miller LLP Announces Investigation of Alliance Healthcare Services, Inc., Alon USA... Apr 28 2017
INVESTOR ALERT: Brower Piven Commences an Investigation Into the Proposed Sale of Alliance... Apr 19 2017
ALLIANCE HEALTHCARE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti,... Apr 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of... Apr 13 2017
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Alliance... Apr 13 2017
ALLIANCE HEALTHCARE SERVICES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation... Apr 12 2017
Alliance HealthCare Services Enters into Definitive Merger Agreement; Transaction Would Result in... Apr 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}